According to the market assessment report titled ‘Global Multiple Sclerosis (MS) Market - Analysis By Drug Class, Route of Administration, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Pipeline and Forecast with Impact of COVID-19 (2021-2026)’, available with MarketStudyReport, global multiple sclerosis (MS) market, valued USD 26.01 billion in the year 2020, is anticipated to garner strong returns by the end of 2027.

Emergence of disease-modifying drugs along with technological advancements in the form of monoclonal bodies, immunosuppressants, immuno-modulators and interferons are the key factors that drive global multiple sclerosis market growth. In addition, mounting number of pipeline drugs and growing consumer inclination towards oral medications are anticipated to broaden the horizon of the market in the upcoming years.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4489504/

Various government and non-government initiatives that focus on improving the life expectancy of people with multiple sclerosis have also induced an upward trend in the growth trajectory of the market.

Apart from this, the study highlights current and upcoming challenges, while also providing precise countermeasures for the same.

Moving on to segmentation, the industry is bifurcated in terms of distribution channel (online pharmacy, retail pharmacy, hospital pharmacy), route of administration (Intravenous, injectable, oral), drug class (immunosuppressants, immunomodulators, interferons, others), and region (North America, Europe, and Asia Pacific). A detailed analysis of each sub-market with respect to historical and future estimates concerning the production volume, value, and growth is encompassed in the document.

Considering the competitive framework Bayer AG, Novartis AG, Teva Pharmaceutical Industries Ltd, GlaxoSmithKline plc (GSK), Pfizer Inc., Biogen Inc., NervGenPharma, EMD Serono Inc., Hoffman La-Roche Ltd., and Bristol Myers- Squibb are the major players impacting global multiple sclerosis (MS) market trends. Established companies are now focusing on R&D activities and clinical trials to launch novel and effective therapies to elevate their position in the marketplace.